Products for Research Use Only
RegisterLogin

Edotreotide

CAT: 0804-HY-106033-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-106033-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) [1][2][3].
CAS Number
204318-14-9
Product Name Alternative
DOTATOC; SDZ-SMT 487; SMT 487
UNSPSC
12352209
Target
Radionuclide-Drug Conjugates (RDCs)
Type
Peptides
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/edotreotide.html
Purity
98.15
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](CO)[C@H](O)C)=O)NC([C@@]([C@H](O)C)([H])NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](NC(CN2CCN(CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6
Molecular Formula
C65H92N14O18S2
Molecular Weight
1421.64
References & Citations
[1]Bushnell DL Jr, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010 Apr 1;28 (10) :1652-9.|[2]Gallicchio R, et al. Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors. Cancer Control. 2023 Jan-Dec;30:10732748231152328.|[3]Capdevila J, et al. A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217) . BMC Cancer. 2025 Apr 4;25 (1) :613.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Launched
Isoform
Other

Alternative Products

CatalogName
MBS5772340Edotreotide
FE175690-01Edotreotide trifluoroacetate

Popular Products